Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines

Experimental work on highly pathogenic viruses such as Ebola virus (EBOV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requires high-level biosafety facilities. Here we provide a detailed step-by-step protocol which details the production and application of replication-incompetent murine leukemia virus (MLV)-based pseudotyped particles to monitor and quantify the viral entry efficiency in human cell lines under bio safety level-2 conditions. We describe the use of viral particles encoding luciferase gene and the quantification of transduction efficiency by measuring luciferase activity.
Graphical Abstract